IP Library Granted Patent US 10,000,500
Granted Patent B2
US 10,000,500 · App. 15/661,582 · Granted Jun 19, 2018

Coelenterazine analogues

Inventors: Mary Hall (Waunakee, WI); Thomas Kirkland (Atascadero, CA); Thomas Machleidt (Madison, WI); Anton Shakhmin (Grover Beach, CA); Joel R. Walker (San Luis Obispo, CA)
Assignee: PROMEGA CORPORATION
C07D487/04A61K49/0021C07D519/00C09K11/06C12Q1/66C12Y113/12005C12Y113/12013C09K2211/1011C09K2211/1018
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,000,500
App. No.
15/661,582
Granted
Jun 19, 2018
Kind
B2
Abstract

Described are coelenterazine analogs, methods for making the analogs, kits comprising the analogs, and methods of using the compounds for the detection of luminescence in luciferase-based assays.

Claims (148)

1. A compound of formula (I)

or a tautomer, or a salt thereof, wherein

R 5 is hydrogen, halogen, hydroxy, cyano, nitro, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, alkoxy, heteroalkyl, aryl, bicyclic aryl, tricyclic aryl, heteroaryl, bicyclic heteroaryl, tricyclic heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl;

R 6 is alkyl, alkenyl, alkynyl, alkoxy, heteroalkyl, aryl, bicyclic aryl, tricyclic aryl, heteroaryl, bicyclic heteroaryl, tricyclic heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; or

R 5 and R 6 together with the atoms to which they are attached, form a 5- or 6-membered partially unsaturated or fully unsaturated ring, the 5- or 6-membered ring optionally containing 1, 2 or 3 heteratoms or heteroatom groups each independently selected from the group consisting of O, N, S, NO, SO and SO 2 as ring members, the 5- or 6-membered ring optionally fused to an aryl, heteroaryl, heterocycle, or cycloalkyl, the 5- or 6-membered ring substituted with 0, 1, 2, 3, or 4 substituents, each independently selected from the group consisting of halogen, ═O, ═S, cyano, nitro, fluoroalkyl, alkoxyfluoroalkyl, fluoroalkoxy, alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, heteroalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl, heteroarylalkyl, arylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkylene, aryloxy, phenoxy, benzyloxy, amino, alkylamino, dialkylamino, acylamino, aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, —COOH, ketone, amide, carbamate, silyl, substituted silyl, t-butyldimethylsilyl, alkylsulfanyl, sulfanyl, and acyl; and

R 8 is alkyl, alkenyl, alkynyl, alkoxy, heteroalkyl, aryl, bicyclic aryl, tricyclic aryl, heteroaryl, bicyclic heteroaryl, tricyclic heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl;

wherein said alkyl, alkenyl, alkynyl, alkoxy, heteroalkyl, aryl, bicyclic aryl, tricyclic aryl, heteroaryl, bicyclic heteroaryl, tricyclic heteroaryl, heterocycle, cycloalkyl, and cycloalkenyl, at each occurrence, are independently substituted with 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 substituents, each independently selected from the group consisting of halogen, ═O, ═S, cyano, nitro, fluoroalkyl, alkoxyfluoroalkyl, fluoroalkoxy, alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, heteroalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl, heteroarylalkyl, arylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkylene, aryloxy, phenoxy, benzyloxy, amino, alkylamino, dialkylamino, acylamino, aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, —COOH, ketone, amide, carbamate, silyl, substituted silyl, t-butyldimethylsilyl, alkylsulfanyl, sulfanyl, and acyl;

provided that the following compounds are excluded from formula (I):

8-benzyl-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one; and

8-benzyl-2-(furan-2-ylmethyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one.

2. The compound of claim 1 , wherein R 5 is hydrogen, cyano, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -haloalkoxy, C 1 -C 6 -alkylamino, C 1 -C 6 -dialkylamino, or phenyl.

3. The compound of claim 1 , wherein R 6 is aryl, bicyclic aryl, tricyclic aryl, biphenyl, heteroaryl, bicyclic heteroaryl, or tricyclic heteroaryl; substituted with 0, 1, 2, or 3 substituents, each independently selected from the group consisting of halogen, hydroxy, cyano, amino, nitro, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -haloalkoxy, C 1 -C 6 -alkylamino, and C 1 -C 6 -dialkylamino.

4. The compound of claim 1 , wherein R 6 is

wherein

X 1 -X 43 are each independently CR 11 or N, wherein R 11 , at each occurrence, is independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, amino, nitro, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -haloalkoxy, C 1 -C 6 -alkylamino, C 1 -C 6 -dialkylamino, and C 1 -C 6 -heteroalkyl; provided that one of X 6 -X 13 is C where the R 6 attaches to the parent molecular formula; provided that one of X 14 -X 23 is C where the R 6 attaches to the parent molecular formula; provided that one of X 24 -X 33 is C where the R 6 attaches to the parent molecular formula; provided that one of X 34 -X 38 is C to attach to the ring containing X 39 -X 43 ;

Y 1 , Y 5 , Y 15 , and Y 22 are O, S, or NR 12 , wherein R 12 is hydrogen, C 1 -C 6 -alkyl, or C 1 -C 6 -haloalkyl;

Y 30 is N;

Y 2 -Y 4 , Y 6 -Y 4 , Y 6 -Y 21 , and Y 23 -Y 29 are each independently CR 13 or N, wherein R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, amino, nitro, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -haloalkoxy, C 1 -C 6 -alkylamino, C 1 -C 6 -dialkylamino, and C 1 -C 6 -heteroalkyl; provided that one of Y 9 -Y 14 is C where the R 6 attaches to the parent molecular formula; provided that one of Y 16 -Y 21 is C where the R 6 attaches to the parent molecular formula; and provided that one of Y 23 -Y 29 is C where the R 6 attaches to the parent molecular formula.

5. The compound of claim 1 , wherein R 6 is selected from the group consisting of:

6. The compound of claim 1 , wherein R 5 and R 6 together with the atoms to which they are attached, form a 6-membered partially unsaturated or fully unsaturated ring, the 6-membered ring optionally containing 1, 2 or 3 heteratoms or heteroatom groups each independently selected from the group consisting of O, N, S, NO, SO and SO 2 as ring members, the 6-membered ring optionally fused to an aryl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycle, or 5-, 6- or 7-membered cycloalkyl, the 6-membered ring and the optionally fused ring each independently substituted with 0, 1, 2, 3, or 4 substituents each independently selected from the group consisting of halogen, ═O, ═S, cyano, nitro, fluoroalkyl, alkoxyfluoroalkyl, fluoroalkoxy, alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, heteroalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl, heteroarylalkyl, arylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkylene, aryloxy, phenoxy, benzyloxy, amino, alkylamino, dialkylamino, acylamino, aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, —COOH, ketone, amide, carbamate, silyl, substituted silyl, t-butyldimethylsilyl, alkylsulfanyl, sulfanyl, and acyl.

7. The compound of claim 1 , wherein R 5 and R 6 together with the atoms to which they are attached, form a ring system selected from the group consisting of:

wherein

Z 1 -Z 10 and Z 13 -Z 16 are each independently CR 14 or N, wherein R 14 , at each occurrence, is independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, amino, nitro, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -haloalkoxy, C 1 -C 6 -alkylamino, C 1 -C 6 -dialkylamino, and C 1 -C 6 -heteroalkyl; and

Z 11 and Z 12 are each independently CR 15 R 16 , NR 17 , O, or S; wherein R 15 and R 16 , at each occurrence, are each independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, amino, nitro, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -haloalkoxy, C 1 -C 6 -alkylamino, C 1 -C 6 -dialkylamino, and C 1 -C 6 -heteroalkyl; and R 17 , at each occurrence, is independently selected from the group consisting of hydrogen, C 1 -C 6 -alkyl, and C 1 -C 6 -haloalkyl.

8. The compound of claim 1 , wherein R 5 and R 6 together with the atoms to which they are attached, form a ring system selected from the group consisting of:

9. The compound of claim 1 , wherein R 8 is aryl, bicyclic aryl, tricyclic aryl, biphenyl, heteroaryl, bicyclic heteroaryl, tricyclic heteroaryl, heterocycle, or cycloalkyl; substituted with 0, 1, 2, or 3 substituents, each independently selected from the group consisting of halogen, ═O, ═S, hydroxy, cyano, amino, nitro, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -haloalkoxy, C 1 -C 6 -alkylamino, and C 1 -C 6 -dialkylamino.

10. The compound of claim 1 , wherein R 8 is

wherein

E 1 -E 43 are each independently CR 21 or N, wherein R 21 , at each occurrence, is independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, amino, nitro, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -haloalkoxy, C 1 -C 6 -alkylamino, C 1 -C 6 -dialkylamino, and C 1 -C 6 -heteroalkyl; provided that one of E 6 -E 13 is C where the R 8 attaches to the parent molecular formula; provided that one of E 4 -E 23 is C where the R 8 attaches to the parent molecular formula; provided that one of E 24 -E 33 is C where the R 8 attaches to the parent molecular formula; provided that one of E 34 -E 38 is C to attach to the ring containing E 39 -E 43 ;

J 1 , J 5 , J 15 , and J 22 are O, S, or NR 22 , wherein R 22 is hydrogen, C 1 -C 6 -alkyl, or C 1 -C 6 -haloalkyl;

J 30 is N;

J 2 -J 4 , J 6 -J 14 , J 16 -J 21 , and J 23 -J 29 are each independently CR 23 or N, wherein R 23 , at each occurrence, is independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, amino, nitro, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -haloalkoxy, C 1 -C 6 -alkylamino, C 1 -C 6 -dialkylamino, and C 1 -C 6 -heteroalkyl; provided that one of J 9 -J 14 is C where the R 8 attaches to the parent molecular formula; provided that one of J 6 -J 21 is C where the R 8 attaches to the parent molecular formula; and provided that one of J 23 -J 29 is C where the R 8 attaches to the parent molecular formula.

11. The compound of claim 1 , wherein R 8 is selected from the group consisting of:

12. The compound of claim 1 , having formula (I-a), (I-b), (I-c), (I-d), or (I-e),

(I-e);

wherein each indicates an optional bond.

13. A compound selected from the group consisting of:

8-benzyl-2-(furan-2-ylmethyl)-6-(naphthalen-1-yl)imidazo[1,2-a]pyrazin-3(7H)-one;

8-benzyl-2-(furan-2-ylmethyl)-6-(naphthalen-2-yl)imidazo[1,2-a]pyrazin-3(7H)-one;

6-(anthracen-9-yl)-8-benzyl-2-(furan-2-ylmethyl)imidazo[1,2-a]pyrazin-3(7H)-one;

8-benzyl-2-(furan-2-ylmethyl)-6-(phenanthren-9-yl)imidazo[1,2-a]pyrazin-3(7H)-one;

6-([1,1′-biphenyl]-4-yl)-8-benzyl-2-(furan-2-ylmethyl)imidazo[1,2-a]pyrazin-3(7H)-one;

8-benzyl-2-(furan-2-ylmethyl)-6-(2-methoxypyrimidin-5-yl)imidazo[1,2-a]pyrazin-3(7H)-one;

4-(8-benzyl-2-(furan-2-ylmethyl)-3-oxo-3,7-dihydroimidazo[1,2-a]pyrazin-6-yl)benzonitrile;

8-benzyl-2-(furan-2-ylmethyl)-6-(quinolin-6-yl)imidazo[1,2-a]pyrazin-3(7H)-one;

8-benzyl-2-(furan-2-ylmethyl)-6-(4-methoxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one;

8-benzyl-2-(furan-2-ylmethyl)-6-(3-methoxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one;

8-benzyl-2-(furan-2-ylmethyl)-6-(2-methoxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one;

8-benzyl-6-(4-fluorophenyl)-2-(furan-2-ylmethyl)imidazo[1,2-a]pyrazin-3(7H)-one;

8-benzyl-2-(furan-2-ylmethyl)-6-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one;

6-(2-aminophenyl)-8-benzyl-2-(furan-2-ylmethyl)imidazo[1,2-a]pyrazin-3(7H)-one;

6-(3-aminophenyl)-8-benzyl-2-(furan-2-ylmethyl)imidazo[1,2-a]pyrazin-3(7H)-one; and

6-(4-aminophenyl)-8-benzyl-2-(furan-2-ylmethyl)imidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-methyl)-6,8-diphenlimidazo[1,2-a]pyrazin-3(7H)-one:

8-cyclopentyl-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-8-(naphthalen-1-yl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one:

2-(furan-2-ylmethyl)-8-(naphthalen-2-yl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

8-([1,1′-biphenyl]-4-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-8-(phenanthren-9-yl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-6-phenyl-8-(phenylethynyl)imidazo[1,2-a]pyrazin-3(7H)-one:

(E)-2-(furan-2-ylmethyl)-6-phenyl-8-styrylimidazo[1,2-a]pyrazin-3(7H)-one;

8-(benzofuran-2-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one:

8-(benzo[b]thiophen-2-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

8-(benzo[c][1,2,5]oxadiazol-5-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-8-(imidazo[1,2-a]pyridin-6-yl)-6-phenylimidazo[1,2-a]pyrazin-3-(7H)-one;

2-(furan-2-ylmethyl)-8-(1H-indol-5-yl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

8-(benzo[d]thiazol-5-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-8-(2-methyl-2H-indazol-6yl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

5-(2-(furan-2-ylmethyl)-3-oxo-6phenyl-3,7-dihydroimidazo[1,2-a]pyrazin-8-yl)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione;

2-(furan-2-ylmethyl)-8-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-8-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl-6-phenyl-8-(3,4,5-trifluorophenyl)imidazo[1,2-a]pyrazin-3(7H)-one;

8-(4-fluorophenyl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-8-(4-nitrophenyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

4-(2-(furan-2-ylmethyl)-3-oxo-6-phenyl-3,7-dihydroimidazo-[1,2-a]pyrazin-8-yl)benzonitrile;

3-(2-(furan-2-ylmethyl)-3-oxo-6-phenyl-3,7-dihydroimidazo[1,2-a]pyrazin-8-yl)benzonitrile;

8-(4-(dimethylamino)phenyl)-2-(furan-2-ylmethyl-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-6-phenyl-8-(thiophen-3-yl)imidazo[1,2-a]pyrazin-3(7H-one;

2-(furan-2-ylmethyl)-6-phenyl-8-(thiophen-2-yl)imidazo[1,2-a]pyrazin-3(7H)-one;

5-(2-(furan-2-ylmethy)-3-oxo-6-phenyl-3,7-dihydroimidazo[1,2-a]pyrazin-8 yl)thiophene-2-carbonitile;

8-(5-chlorothiophen-2-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2a]pyrazin-3(7H)-one;

8-(3-chlorothiophen-2-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2ylmethyl)-6-phenyl-8-(pyridin-3-yl)imidazo[1,2-a]pyrazin-3(7H)-one;

8-(6-fluoropyridin-3-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

8-(2-fluoropyridin-3-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

8-(2-chloropyridin-3-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-6-phenyl-8-(pyridin-4-yl)imidazo[1,2-a]pyrazin-3(7H)-one;

8-(2-fluoropyridin-4 yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

8-(2-chloropyridin-4-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-6-phenyl-8-(quinolin-4-yl)imidazol[1,2-a]pyrazin-3(7H)-one;

8-(2,6-dichloropyridin-4-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-6-phenyl-8-(2-(trifluoromethyl)pyridin-4-yl)imidazol[1,2-a]pyrazin-3(7H)-one;

8-(2-bromopyridin-4-yl)-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3 (7H)-one;

2-(furan-2-ylmethyl)-6-phenyl-8-(thiazol-5-yl)imidazol[1,2-a]pyrazin-3(7H)-one; and

5-(2-(furan-2-ylmethyl)-3-oxo-6 phenyl-3,7-dihydroimidazo[1,2-a]pyrazin-8-yl)-1-methyl-1H-pyrrole-2-carbonitrile;

6,8-difuran-2-yl)-2-(furan-2-ylmethyl)imidazo[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-6,8-di(thiophen-2-yl)imidazo[1,2a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-6-(1-methyl-1H-pyrazol-3-yl)-8-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-3(7H)-one;

8-(2-fluoropyridin-4-yl)-2-(furan-2-ylmethyl)-6-(thiophen-2-yl)imidazo[1,2-a]pyrazin-3(7H)-one;

5-(2-(furan-2-ylmethyl)-3-oxo-6-(thiophen-2-yl)-3,7-dihydroimidazo[1,2-a]pyrazin-8-yl)thiophene-2-carbonitrile;

26,8-bis(2-fluoropyridin-4-yl)-2-(furan-2-ylmethyl)imidazol[1,2-a]pyrazin-3(7H)-one;

2-(furan-2-ylmethyl)-6-phenyl-8-(phenylethynyl)imidazo[1,2-a]pyrazin-3(7H)-one;

6-(4-aminophenyl)-2-(furan-2-ylmethyl)-8(quinolin-4-yl)imidazol[1,2-a]pyrazin-3(7H)-one;

5-(6-(4-aminophenyl)-2-(furan-2-ylmethyl)-3-oxo-3,7-dihydroimidazo[1,2-a]pyrazin-8-yl)thiophene-2-carbonitile;

6,8-bis(4-aminophenyl)-2-(furan-2-ylmethyl)imidazo[1,2-a]pyrazin-3(7H)-one,

2-(furan-2-ylmethyl)-6-(4-hydroxyphenyl)-8-(quinolin-4-yl)imidazo[1,2-a]pyrazin-3(7H)-one; and

5-(2-furan-2-ylmethyl)-6-(4-hydroxyphenyl)-3-oxo-3,7-dihydroimidazo[1,2-a]pyrazin-8-yl)thiophene-2-carbonitrile;

2-(furan-2-ylmethyl)-5,6,8-triphenylimidazo[1,2-a]pyrazin-3(7H)-one; and

2-(furan-2-ylmethyl)-3-oxo-6,8-diphenyl-3,7-dihydroimidazo[1,2-a]pyrazine-5-carbonitrile;

4-(2-chloropyridin-4-yl)-2-(furan-2-ylmethyl)imidazo[1,2-a]quinoxalin-1(5H)-one;

5-(2-(furan-2-ylmethyl)-1-oxo-1,5-dihydroimidazo[1,2-a]quinoxalin-4-yl)thiophene-2-carbonitrile;

12-(2-chloropyridin-4-yl)-2-(furan-2-ylmethyl)-5,11-dihydrobenzo[f]imidazo[1,2-a]quinoxalin-3(6H)-one;

5-(2-(furan-2-ylmethyl)-3-oxo-3,5,6,11-tetrahydrobenzo[f]imidazo[1,2-a]quinoxalin-12-yl)thiophene-2-carbonitrile; and

2-(furan-2-ylmethyl)-12-(quinolin-4-yl)-5,11-dihydrobenzo[f′]imidazo[1,2-a]quinoxalin-3(6H)-one;

8-(2-chloropyridin-4 yl)-2-(furan-2-ylmethyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one;

12-(2-chloropyridin-4-yl)-2-(furan-2-ylmethyl)benzo[f]imidazo[1,2-a]quinoxalin-3(11H)-one,

5-(2-(furan-2-ylmethyl)-3-oxo-3,11-dihydrobenzo[f]imidazo[1,2-a]quinoxalin-12-yl)thiophene-2-carbonitile; and

2-(furan-2-ylmethyl)-12-(quinolin-4-yl)benzo[f′]imidazo[1,2-a]quinoxalin-3(11H)-one;

2-benzyl-5-ethynyl-6,8-diphenylimidazo[1,2-a]pyrazin-3(7H)-one;

2-benzyl-3-oxo-6,8-diphenyl-3,7-dihydroimidazo[1,2-a]pyrazine-5-carbonitrile

2-benzyl-5-(dimethylamino)-6,8-diphenylimidazo[1,2-a]pyrazin-3(7H)-one; and

2-benzyl-5-methoxy-6,8-diphenylimidazo[1,2-a]pyrazin-3(7H)-one;

or a tautomer, or a salt thereof.

14. A compound of formula (II),

or a tautomer, or a salt thereof, wherein

R x is halogen, hydroxy, cyano, nitro, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, alkoxy, heteroalkyl, aryl, bicyclic aryl, tricyclic aryl, heteroaryl, bicyclic heteroaryl, tricyclic heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl;

p is 0, 1, 2, 3, 4, or 5;

R 5a is hydrogen, halogen, hydroxy, cyano, nitro, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, alkoxy, heteroalkyl, aryl, bicyclic aryl, tricyclic aryl, heteroaryl, bicyclic heteroaryl, tricyclic heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl;

R 6a is alkyl, alkenyl, alkynyl, alkoxy, heteroalkyl, aryl, bicyclic aryl, tricyclic aryl, heteroaryl, bicyclic heteroaryl, tricyclic heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; or

R 5a and R 6a together with the atoms to which they are attached, form a 5- or 6-membered partially unsaturated or fully unsaturated ring, the 5- or 6-membered ring optionally containing 1, 2 or 3 heteratoms or heteroatom groups each independently selected from the group consisting of O, N, S, NO, SO and SO 2 as ring members, the 5- or 6-membered ring optionally fused to an aryl, heteroaryl, heterocycle, or cycloalkyl, the 5- or 6-membered ring substituted with 0, 1, 2, 3, or 4 substituents, each independently selected from the group consisting of halogen, ═O, ═S, cyano, nitro, fluoroalkyl, alkoxyfluoroalkyl, fluoroalkoxy, alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, heteroalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl, heteroarylalkyl, arylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkylene, aryloxy, phenoxy, benzyloxy, amino, alkylamino, dialkylamino, acylamino, aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, —COOH, ketone, amide, carbamate, silyl, substituted silyl, t-butyldimethylsilyl, alkylsulfanyl, sulfanyl, and acyl; and

R 8a is alkyl, alkenyl, alkynyl, alkoxy, heteroalkyl, aryl, bicyclic aryl, tricyclic aryl, heteroaryl, bicyclic heteroaryl, tricyclic heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl;

wherein said alkyl, alkenyl, alkynyl, alkoxy, heteroalkyl, aryl, bicyclic aryl, tricyclic aryl, heteroaryl, bicyclic heteroaryl, tricyclic heteroaryl, heterocycle, cycloalkyl, and cycloalkenyl, at each occurrence, are independently substituted with 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 substituents, each independently selected from the group consisting of halogen, ═O, ═S, cyano, nitro, fluoroalkyl, alkoxyfluoroalkyl, fluoroalkoxy, alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, heteroalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl, heteroarylalkyl, arylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkylene, aryloxy, phenoxy, benzyloxy, amino, alkylamino, dialkylamino, acylamino, aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, —COOH, ketone, amide, carbamate, silyl, substituted silyl, t-butyldimethylsilyl, alkylsulfanyl, sulfanyl, and acyl;

provided that R x is not 4-hydroxy when p is 1, R 5a is not hydrogen, or R 8a is not benzyl, or any combination thereof.

15. A kit comprising a compound of claim 1 .

16. A method for detecting luminescence in a sample, the method comprising

contacting a sample with a compound of claim 1 ;

contacting the sample with a coelenterazine-utilizing luciferase, if it is not present in the sample; and

detecting luminescence.

17. A method for detecting luminescence in a transgenic animal comprising

administering a compound of claim 1 to a transgenic animal; and detecting luminescence;

wherein the transgenic animal expresses a coelenterazine-utilizing luciferase.

18. A kit comprising a compound of claim 14 .

19. A method for detecting luminescence in a sample, the method comprising contacting a sample with a compound of claim 14 ;

contacting the sample with a coelenterazine-utilizing luciferase, if it is not present in the sample; and

detecting luminescence.

20. A method for detecting luminescence in a transgenic animal comprising administering a compound of claim 14 to a transgenic animal; and

detecting luminescence;

wherein the transgenic animal expresses a coelenterazine-utilizing luciferase.

Assignments (2)
SECURITY INTEREST Recorded Apr 3, 2019
From: PROMEGA CORPORATION; PROMEGA BIOSCIENCES, LLC; TERSO SOLUTIONS, INC.; ORION SEVEN, LLC; PROMEGA AVIATION LLC
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 048790/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2017
From: HALL, MARY; KIRKLAND, THOMAS; MACHLEIDT, THOMAS; SHAKHMIN, ANTON; WALKER, JOEL R.
To: PROMEGA CORPORATION
Reel/Frame 043137/0353 →
Continuity (2)
Provisional Application 62367689 · Jul 28, 2016
Related Publication 20180030059A1 · Feb 1, 2018